A carregar...
Publicação
Intrinsic valuation and sensitivity analysis on DiaSorin S.p.A. DiaSorin S.p.A.
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 4.28 MB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
This report provides a comprehensive analysis of DiaSorin S.p.A., assessing its financial performance, strategic positioning, and long-term value potential. Despite post-COVID normalization and the integration of Luminex increasing operational complexity, DiaSorin maintains solid fundamentals, strong cash generation, and a diversified diagnostics portfolio. Our DCF and trading comparables analyses indicate meaningful upside relative to the current share price, supported by resilient core revenues and improving profitability. The company’s strengthened ESG framework and disciplined capital structure further enhance its investment appeal. Overall, DiaSorin is well positioned for
sustainable growth driven by innovation, geographic expansion, and operational integration benefits.
Descrição
Palavras-chave
DiaSorin Diagnostics Immunodiagnostics Molecular diagnostics Luminex acquisition Financial analysis Revenue growth EBITDA EBIT Profitability Cash flow Net working capital Capital structure Net debt Valuation DCF model Trading comparables Multiples valuation ESG strategy Sustainability Governance Market positioning Competitive landscape Innovation pipeline Strategic synergies Healthcare sector Diagnostics market Investment thesis Equity research Italy Life sciences